

Supplementary Table 1 Clinicopathologic characteristics of patients with post-hepatectomy portal vein thrombosis

Cases	Age (yr)	Sex	Disease	Extent of resection	PVT location	Dx	diagnosis	treatment	Clavien-Dindo grade	Outcome
1	58	F	PHCC	H1234-B	MPV	32	CT	Anticoagulant	II	Resolved
2	67	M	HCC	H5678	MPV	12	BUS/CT	Anticoagulant	II	Stable
3	57	M	HCC	H2345'8'	PPV	6	CT	Anticoagulant	II	Stable
4	53	F	intrahepatic lithiasis	H1'234-B	MPV+PPV	7	CT	Anticoagulant	II	Resolved
5	68	M	HCC	H4'5678-PV	MPV	8	BUS/CT	Anticoagulant	II	Resolved
6	45	M	PHCC	H123458-B-PV	MPV+SV	2	BUS/CT	Anticoagulant+Operation	V	Death
7	46	F	HCC	H67	PPV	5	CT	Anticoagulant	II	Resolved

										ed
8	50	F	PHCC	H15678-B	MPV	2	CT	Anticoagulant+Operation	III	Resolved
9	52	M	ICC	H234	MPV	7	CT	Anticoagulant	V	Death
10	32	M	HCC	H5678	MPV+SV	2	BUS/C T	Anticoagulant+Thrombolysis	III	Resolved
11	64	F	primary biliary dilation	H234	MPV	3	BUS/C T	Anticoagulant+Thrombolysis+ Operation	V	Death
12	37	F	HCC	H5678	MPV	5	CT	Anticoagulant	II	Stable
13	65	M	PHCC	H145678-B-P V	MPV+SV+S MV	3	BUS/C T	Anticoagulant+Thrombolysis	V	Death
14	56	M	GBca	H45678-B-PV -PD	MPV	1	BUS/C T	Anticoagulant+Operation	V	Death
15	78	M	GBca	H45678-B-PV -PD	MPV+SV	3	BUS/C T	Anticoagulant+Thrombolysis	V	Death
16	65	F	PHCC	H15678-B	MPV	6	CT	Anticoagulant	II	Resolved

											ed
17	53	M	PHCC	H15678-B-PV	MPV+SMV	7	CT	Anticoagulant	II	Stable	
18	48	M	PHCC	H5678-B-PV- PD	MPV+PPV	1	CT	Anticoagulant+Operation	V	Death	
19	53	F	PHCC	H15678-B-PV	MPV	15	CT	Anticoagulant	II	Stable	
20	54	M	PHCC	H15678-B-PV	MPV	8	CT	Anticoagulant	II	Resolv ed	
21	75	M	PHCC	H123458-B	MPV	5	CT	Anticoagulant+Thrombolysis	III	Resolv ed	
22	60	M	intrahepati c lithiasis	H5678-B-PV	MPV	1	BUS/C T	Anticoagulant+Operation	III	Resolv ed	
23	58	F	PHCC	H15678-B-PV	MPV+PPV	9	CT	Anticoagulant+Thrombolysis	V	Death	
24	34	M	PHCC	H123458-B	MPV+SV	2	BUS/C T	Anticoagulant+Operation	III	Resolv ed	
25	29	F	intrahepati c lithiasis	H5678-B	PPV	16	CT	Anticoagulant	II	Stable	
26	70	M	PHCC	H15678-B	MPV	5	CT	Anticoagulant+Thrombolysis	III	Resolv	

											ed
27	48	F	PHCC	H15678-B-PV	MPV+SMV	2	BUS/C T	Anticoagulant+Operation	III	Resolv ed	
28	38	F	hepatic echinococc osis	H23458-B-PV -HV	MPV	7	CT	Anticoagulant	II	Stable	
29	52	M	hepatic echinococc osis	H45678-B-PV	MPV	1	BUS/C T	Anticoagulant+Operation	III	Resolv ed	
30	61	F	ICC	H1234-PV-H V	MPV+SMV	3	BUS/C T	Anticoagulant+Thrombolysis	V	Death	
31	65	M	HCC	H5678-PV	MPV	4	BUS/C T	Anticoagulant+Operation	III	Resolv ed	
32	45	M	HCC	H2348	PPV	24	CT	Anticoagulant	II	Stable	
33	36	M	ICC	H5678	MPV	19	CT	Anticoagulant	II	Stable	
34	67	F	PHCC	H15678-B-PV -PD	MPV+SV+S MV	5	BUS/C T	Anticoagulant+Operation	V	Death	

35	57	F	hepatic echinococ- cosis	H234	MPV	3	BUS/C T	Anticoagulant+Thrombolysis	III	Resolv ed
36	64	M	HCC	H4b	PPV	8	CT	None	I	Resolv ed
37	74	F	GBca	H45-PD	MPV+SV+S MV	7	CT	Anticoagulant	V	Death
38	64	F	PHCC	H1234-B-PV	MPV	15	CT	Anticoagulant+Thrombolysis	V	Death
39	57	M	HCC	H7	MPV+PPV	8	CT	Anticoagulant	II	Stable
40	72	F	PHCC	H1234-B-PV	MPV	24	BUS/C T	Anticoagulant	V	Death
41	62	M	PHCC	H123458--B-P D	MPV	17	CT	Anticoagulant	V	Death
42	69	F	PHCC	H14b5678-B- PV	MPV	9	BUS/C T	Anticoagulant+Operation	V	Death

M: male; F: female; HCC: hepatocellular carcinoma; PHCC: perihilar cholangiocarcinoma; GBca: gallbladder carcinoma; ICC: intrahepatic cholangiocarcinoma; Dx: days of diagnosis; BUS: B-mode ultrasound; CT: computed tomography; PV: portal vein;

MPV main portal vein; PPV peripheral portal vein; SV: splenic vein; SMV: superior mesenteric vein; HV: hepatic vein; PD: pancreaticoduodenectomy.

Supplementary Table 2 Comparison of clinical characteristics between alive group and death group

Characteristics	Alive	Death	P value	Method
n	27	15		
Age, n			0.003	χ^2
<60	20	4		
≥60	7	11		
Gender, n			0.432	χ^2
Male	16	7		
Female	11	8		
BMI, mean ± sd	23.90 ± 2.82	22.68 ± 3.23	0.208	T test
Diseases, n			0.028	Yates' correction
biliary tract cancer	12	13		
hepatocellular carcinoma	9	1		
benign disease	6	1		
Liver cirrhosis, n			0.117	Yates' correction
yes	9	1		
no	18	14		

Major hepatectomy, n			1.000	Yates' correction
yes	24	14		
no	3	1		
Caudate lobectomy, n			0.394	χ^2
yes	9	7		
no	18	8		
Pancreaticoduodenectomy, n			0.002	Yates' correction
yes	0	6		
no	27	9		
Portal vein reconstruction, n			0.013	χ^2
yes	9	11		
no	18	4		
Hepatic vein reconstruction, n			1.000	Yates' correction
yes	1	1		
no	26	14		
Bile duct resection, n			0.172	χ^2
yes	16	12		

no	11	3		
Operation time (min), mean $\pm$ sd	618.59 $\pm$ 219.90	740.60 $\pm$ 191.47	0.079	<i>t</i> test
Blood loss (mL), median (IQR)	400 (200, 600)	400 (200, 800)	0.490	Wilcoxon
Blood transfusion, n			0.495	χ^2
yes	17	11		
no	10	4		
Postoperative portal vein angle			1.000	Fisher test
$\geq 100^\circ$	10	6		
$< 100^\circ$	14	8		
Main portal vein diameter (mm), median (IQR)	11 (10, 12)	11 (8.5, 13)	0.873	Wilcoxon
Pringle maneuver(min), median (IQR)	60.5 (49.7, 106.2)	86.2 (68.6, 133.6)	0.093	Wilcoxon
Preoperative laboratory test				
Platelet count ($9 \times 10^4/\mu\text{L}$), median (IQR)	174 (127.5, 264.5)	175 (145.5, 216)	0.948	Wilcoxon
PTINR, median (IQR)	1.05 (0.98, 1.11)	0.99 (0.96, 1.02)	0.124	Wilcoxon
FDP ($\mu\text{g/mL}$), median (IQR)	2.5 (2.5, 3.7)	2.5 (2.5, 3.18)	0.975	Wilcoxon
Ddimer ($\mu\text{g/mL}$), median (IQR)	0.45 (0.31, 2.24)	0.76 (0.15, 1.10)	0.461	Wilcoxon
Postoperative laboratory test				

Platelet count (9*10 ⁴ /uL), mean ± sd	137.2 ± 65.5	108.9 ± 51.5	0.156	<i>t</i> test
PTINR, median (IQR)	1.23 (1.18, 1.36)	1.26 (1.16, 1.44)	0.803	Wilcoxon
FDP (µg/mL), mean ± sd	30.8 ± 20.3	42.6 ± 27.6	0.119	<i>t</i> test
Ddimer (µg/mL), median (IQR)	9.50 (7.42, 16.38)	13.65 (7.49, 19.18)	0.391	Wilcoxon

PTINR: prothrombin time-international normalized ratio; FDP: fibrinogen degradation product; BMI: body mass index; IQR: interquartile range.